Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics

Core Insights - Amedisys reported revenue of $571.41 million for Q1 2024, a year-over-year increase of 2.7% and an EPS of $1.03, up from $1.00 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $564.58 million by 1.21%, while the EPS also surpassed the consensus estimate of $1.01 by 1.98% [1] Revenue Breakdown - Net Service Revenue from Home Health was $364 million, exceeding the average estimate of $358.15 million, reflecting a year-over-year increase of 6% [2] - Net Service Revenue from High Acuity Care reached $6.40 million, surpassing the estimated $6.20 million, with a significant year-over-year increase of 36.2% [2] - Net Service Revenue from Hospice was $201 million, slightly below the average estimate of $202.55 million, but still showing a year-over-year increase of 3.9% [2] Stock Performance - Amedisys shares have returned -1.2% over the past month, compared to a -3% change in the Zacks S&P 500 composite [2] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [2]